<?xml version="1.0" encoding="UTF-8"?>
<html><body class="spl" id="spl">
<div class="DocumentTitle"><p class="DocumentTitle"><strong>ILUVIEN- fluocinolone acetonide implant </strong><br>Alimera Sciences, Inc.<br></p></div>
<div id="Highlights" class="Highlights"><table cellspacing="5" cellpadding="5" width="100%" style="table-layout:fixed"><tr><td align="left" valign="top"><div>
<h1>HIGHLIGHTS OF PRESCRIBING INFORMATION</h1>
<div class="HighlightsDisclaimer"><span class="Bold">These highlights do not include all the information needed to use ILUVIEN® safely and effectively. See full prescribing information for ILUVIEN.
			<br><br>ILUVIEN® (fluocinolone acetonide intravitreal implant) <br>0.19 mg
			<br>For Intravitreal Injection
			<br>Initial U.S. Approval: 1963
		</span></div>
<div></div>
<div class="HighlightSection">
<h1 class="Highlights"><span>INDICATIONS AND USAGE</span></h1>
<div><p class="Highlighta"><span class="Bold">ILUVIEN </span>contains a corticosteroid and is indicated for the treatment of <span class="product-label-link" type="condition" conceptid="380097" conceptname="Diabetic macular edema">diabetic macular edema</span> in patients who have been previously treated with a course of corticosteroids and did not have a clinically significant rise in intraocular pressure. <a href="#LH014400e472-7402-11df-93f2-0800200c9a66">(1)</a> </p></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>DOSAGE AND ADMINISTRATION</span></h1>
<div><ul>
<li>For ophthalmic intravitreal injection. <a href="#LH0214400e473-7402-11df-93f2-0800200c9a66">(2.1)</a>
</li>
<li>The intravitreal injection procedure should be carried out under aseptic conditions. <a href="#LH0224400e475-7402-11df-93f2-0800200c9a66">(2.2)</a>
</li>
<li>Following the intravitreal injection, patients should be monitored for elevation in intraocular pressure and for <span class="product-label-link" type="condition" conceptid="438411" conceptname="Endophthalmitis">endophthalmitis</span>. <a href="#LH0224400e475-7402-11df-93f2-0800200c9a66">(2.2)</a>
</li>
</ul></div>
<div></div>
<div></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>DOSAGE FORMS AND STRENGTHS</span></h1>
<div><p class="Highlighta">Non-bioerodable intravitreal implant containing 0.19 mg fluocinolone acetonide in a drug delivery system. <a href="#LH034400e476-7402-11df-93f2-0800200c9a66">(3)</a> </p></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>CONTRAINDICATIONS</span></h1>
<div><ul>
<li>Ocular or periocular <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infections</span> <a href="#LH0414400e478-7402-11df-93f2-0800200c9a66">(4.1)</a>
</li>
<li><span class="product-label-link" type="condition" conceptid="437541" conceptname="Glaucoma">Glaucoma</span> <a href="#LH0424400e479-7402-11df-93f2-0800200c9a66">(4.2)</a>
</li>
<li><span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">Hypersensitivity</span> <a href="#LH0434400e47a-7402-11df-93f2-0800200c9a66">(4.3)</a>
</li>
</ul></div>
<div></div>
<div></div>
<div></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>WARNINGS AND PRECAUTIONS</span></h1>
<div><ul>
<li>Intravitreal injections have been associated with <span class="product-label-link" type="condition" conceptid="438411" conceptname="Endophthalmitis">endophthalmitis</span>, <span class="product-label-link" type="condition" conceptid="376709" conceptname="Discharge of eye">eye inflammation</span>, <span class="product-label-link" type="condition" conceptid="4011560" conceptname="Raised intraocular pressure">increased intraocular pressure</span>, and <span class="product-label-link" type="condition" conceptid="378414" conceptname="Retinal detachment">retinal detachments</span>. Patients should be monitored following the injection.  <a href="#LH0514400e47c-7402-11df-93f2-0800200c9a66">(5.1)</a>
</li>
<li>Use of corticosteroids may produce <span class="product-label-link" type="condition" conceptid="375256" conceptname="Anterior subcapsular polar senile cataract">posterior subcapsular cataracts</span>, <span class="product-label-link" type="condition" conceptid="4011560" conceptname="Raised intraocular pressure">increased intraocular pressure</span>, <span class="product-label-link" type="condition" conceptid="437541" conceptname="Glaucoma">glaucoma</span>, and may enhance the establishment of secondary ocular <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infections</span> due to bacteria, fungi, or viruses.  <a href="#LH0524400e47d-7402-11df-93f2-0800200c9a66">(5.2)</a>
</li>
<li>The implant may migrate into the anterior chamber if the posterior lens capsule is not intact. <a href="#LH0534400f50a9566-2c43-11e4-8c21-0800200c9a66">(5.3)</a>
</li>
</ul></div>
<div></div>
<div></div>
<div></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>ADVERSE REACTIONS</span></h1>
<div>
<p class="Highlighta">In controlled studies, the most common adverse reactions reported were <span class="product-label-link" type="condition" conceptid="375545" conceptname="Cataract">cataract</span> development and increases in intraocular pressure.  <a href="#LH0614400e47f-7402-11df-93f2-0800200c9a66">(6.1)</a> </p>
<br><p class="Highlighta"><span class="Bold">To report SUSPECTED ADVERSE REACTIONS, contact Alimera Sciences, Inc. at 1-844-445-8843 or FDA at 1-800-FDA-1088 or <span class="Underline">www.fda.gov/medwatch</span>.</span> </p>
<p class="Highlighta">    </p>
</div>
<div></div>
<div></div>
</div>
<div>
<div></div>
<div></div>
<div></div>
</div>
<div></div>
<div>
<div></div>
<div></div>
</div>
<div><div></div></div>
<div></div>
<div><div></div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<p class="HighlightsSeeReference">See 17 for PATIENT COUNSELING INFORMATION.</p>
<p class="HighlightsRevision">Revised: 9/2014</p>
</div></td></tr></table></div>
<div id="Index" class="Index"><table cellspacing="5" cellpadding="5" width="100%" style="table-layout:fixed"><tr><td align="left" valign="top"><div>
<h1 class="Colspan">FULL PRESCRIBING INFORMATION: CONTENTS<a href="#footnote-content" name="footnote-reference-content">*</a>
</h1>
<h1><a href="#section-1" class="toc">1  INDICATIONS AND USAGE</a></h1>
<h1><a href="#section-2" class="toc">2  DOSAGE AND ADMINISTRATION</a></h1>
<h2><a href="#section-2.1" class="toc">2.1 General Dosing Information</a></h2>
<h2><a href="#section-2.2" class="toc">2.2 Administration</a></h2>
<h1><a href="#section-3" class="toc">3  DOSAGE FORMS AND STRENGTHS</a></h1>
<h1><a href="#section-4" class="toc">4  CONTRAINDICATIONS</a></h1>
<h2><a href="#section-4.1" class="toc">4.1 Ocular or Periocular <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">Infections</span></a></h2>
<h2><a href="#section-4.2" class="toc">4.2 <span class="product-label-link" type="condition" conceptid="437541" conceptname="Glaucoma">Glaucoma</span></a></h2>
<h2><a href="#section-4.3" class="toc">4.3 <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">Hypersensitivity</span></a></h2>
<h1><a href="#section-5" class="toc">5  WARNINGS AND PRECAUTIONS</a></h1>
<h2><a href="#section-5.1" class="toc">5.1  Intravitreal Injection-related Effects</a></h2>
<h2><a href="#section-5.2" class="toc">5.2  Steroid-related Effects</a></h2>
<h2><a href="#section-5.3" class="toc">5.3   Risk of Implant Migration</a></h2>
<h1><a href="#section-6" class="toc">6  ADVERSE REACTIONS</a></h1>
<h2><a href="#section-6.1" class="toc">6.1 Clinical Studies Experience</a></h2>
<h2><a href="#section-6.2" class="toc">6.2 Postmarketing Experience</a></h2>
<h1><a href="#section-7" class="toc">8  USE IN SPECIFIC POPULATIONS</a></h1>
<h2><a href="#section-7.1" class="toc">8.1  Pregnancy</a></h2>
<h2><a href="#section-7.2" class="toc">8.3 Nursing Mothers</a></h2>
<h2><a href="#section-7.3" class="toc">8.4  Pediatric Use</a></h2>
<h2><a href="#section-7.4" class="toc">8.5  Geriatric Use</a></h2>
<h1><a href="#section-8" class="toc">11  DESCRIPTION</a></h1>
<h1><a href="#section-9" class="toc">12  CLINICAL PHARMACOLOGY</a></h1>
<h2><a href="#section-9.1" class="toc">12.1  Mechanism of Action</a></h2>
<h2><a href="#section-9.2" class="toc">12.3  Pharmacokinetics</a></h2>
<h1><a href="#section-10" class="toc">13  NONCLINICAL TOXICOLOGY</a></h1>
<h2><a href="#section-10.1" class="toc">13.1  Carcinogenesis, Mutagenesis, Impairment of Fertility</a></h2>
<h1><a href="#section-11" class="toc">14  CLINICAL STUDIES</a></h1>
<h1><a href="#section-12" class="toc">16  HOW SUPPLIED/STORAGE AND HANDLING</a></h1>
<h1><a href="#section-13" class="toc">17  PATIENT COUNSELING INFORMATION</a></h1>
<dl class="Footnote">
<dt><a href="#footnote-reference-content" name="footnote-content">*</a></dt>
<dd>Sections or subsections omitted from the full prescribing information are not listed.</dd>
</dl>
</div></td></tr></table></div>
<div class="Contents">
<h1>FULL PRESCRIBING INFORMATION</h1>
<div class="Section" data-sectionCode="48780-1">
<a name="section-1"></a><p></p>
</div>
<div class="Section" data-sectionCode="34067-9">
<a name="LH014400e472-7402-11df-93f2-0800200c9a66"></a><a name="section-1"></a><p></p>
<h1>1  INDICATIONS AND USAGE</h1>
<p class="First"><span class="Bold">ILUVIEN®</span> (fluocinolone acetonide intravitreal implant) 0.19 mg is indicated for the treatment of <span class="product-label-link" type="condition" conceptid="380097" conceptname="Diabetic macular edema">diabetic macular edema</span> in patients who have been previously treated with a course of corticosteroids and did not have a clinically significant rise in intraocular pressure. </p>
</div>
<div class="Section" data-sectionCode="34068-7">
<a name="LH0214400e474-7402-11df-93f2-0800200c9a66"></a><a name="section-2"></a><p></p>
<h1>2  DOSAGE AND ADMINISTRATION</h1>
<div class="Section" data-sectionCode="42229-5">
<a name="LH0214400e473-7402-11df-93f2-0800200c9a66"></a><a name="section-2.1"></a><p></p>
<h2>2.1 General Dosing Information</h2>
<p class="First">For ophthalmic intravitreal injection.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="LH0224400e475-7402-11df-93f2-0800200c9a66"></a><a name="section-2.2"></a><p></p>
<h2>2.2 Administration</h2>
<p class="First">The intravitreal injection procedure should be carried out under  aseptic conditions, which include the use of sterile gloves, a sterile drape, a sterile caliper, and a sterile eyelid speculum (or equivalent).  Adequate anesthesia and a broad-spectrum microbicide should be given prior to the injection.</p>
<p>The injection procedure for <span class="Bold">ILUVIEN</span> is as follows:<br><br></p>
<ol>
<li>The exterior of the tray should <span class="Bold Italics">not</span> be considered sterile.  An assistant (non-sterile) should remove the tray from the carton and examine the tray and lid for damage. If damaged, do not use unit. <br>If acceptable, the assistant should peel the lid from the tray <span class="Bold Italics">without touching the interior surface.</span>
</li>
<li>Visually check through the viewing window of the preloaded applicator to ensure that there is a drug implant inside.</li>
<li>Remove the applicator from the tray with sterile gloved hands <span class="Bold Italics">touching only the sterile interior tray surface and applicator. </span><br>The protective cap on the needle should not be removed until the patient is ready to be injected.
										<br>Prior to injection, the applicator tip must be kept above the horizontal plane to ensure that the implant is properly positioned within the applicator.
									</li>
<li>To reduce the amount of air administered with the implant, the administration procedure requires two steps.  Before inserting the needle into the eye, push the applicator button down and slide it to the first stop (at the curved black marks alongside the button track). At the first stop, release the button and it should move to the UP position.  If the button does not rise to the UP position, do not proceed with this unit.</li>
<li>Optimal placement of the implant is inferior to the optic disc and posterior to the equator of the eye.  Measure 4 millimeters inferotemporal from the limbus with the aid of calipers for point of entry into the sclera.</li>
<li>Carefully remove the protective cap from the needle and inspect the tip to ensure it is not bent.  </li>
<li>Gently displace the conjunctiva so that after withdrawing the needle, the conjunctival and scleral needle entry sites will not align. Care should be taken to avoid contact between the needle and the lid margin or lashes. Insert the needle through the conjunctiva and sclera. To release the implant, while the button is in the UP position, advance the button by sliding it forward to the end of the button track and remove the needle. Note: Ensure that the button reaches the end of the track before removing the needle. </li>
<li>Remove the lid speculum and perform indirect ophthalmoscopy to verify placement of the implant, adequate central retinal artery perfusion and absence of any other complications.</li>
</ol>
<p>Following the injection, patients should be monitored for elevation in intraocular pressure and for <span class="product-label-link" type="condition" conceptid="438411" conceptname="Endophthalmitis">endophthalmitis</span>.  Monitoring may consist of a check for perfusion of the optic nerve head immediately after the injection, tonometry within 30 minutes following the injection, and biomicroscopy between two and seven days following the injection.  Patients should be instructed to report without delay any symptoms suggestive of <span class="product-label-link" type="condition" conceptid="438411" conceptname="Endophthalmitis">endophthalmitis</span>.</p>
</div>
</div>
<div class="Section" data-sectionCode="43678-2">
<a name="LH034400e476-7402-11df-93f2-0800200c9a66"></a><a name="section-3"></a><p></p>
<h1>3  DOSAGE FORMS AND STRENGTHS</h1>
<p class="First"><span class="Bold">ILUVIEN</span> is a non-bioerodable intravitreal implant in a drug delivery system containing 0.19 mg fluocinolone acetonide, designed to release fluocinolone acetonide at an initial rate of 0.25 μg/day and lasting 36 months. </p>
</div>
<div class="Section" data-sectionCode="34070-3">
<a name="LH044400e477-7402-11df-93f2-0800200c9a66"></a><a name="section-4"></a><p></p>
<h1>4  CONTRAINDICATIONS</h1>
<div class="Section" data-sectionCode="42229-5">
<a name="LH0414400e478-7402-11df-93f2-0800200c9a66"></a><a name="section-4.1"></a><p></p>
<h2>4.1 Ocular or Periocular <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">Infections</span></h2>
<p class="First"><span class="Bold">ILUVIEN</span> is contraindicated in patients with active or suspected ocular or periocular <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infections</span> including most viral disease of the cornea and conjunctiva including active epithelial <span class="product-label-link" type="condition" conceptid="373404" conceptname="Ophthalmic herpes simplex">herpes simplex keratitis</span> (<span class="product-label-link" type="condition" conceptid="373404" conceptname="Ophthalmic herpes simplex">dendritic keratitis</span>), <span class="product-label-link" type="condition" conceptid="140633" conceptname="Vaccinia">vaccinia</span>, <span class="product-label-link" type="condition" conceptid="434272" conceptname="Varicella">varicella</span>, <span class="product-label-link" type="condition" conceptid="4009326" conceptname="Mycobacterial infection">mycobacterial infections</span> and fungal diseases.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="LH0424400e479-7402-11df-93f2-0800200c9a66"></a><a name="section-4.2"></a><p></p>
<h2>4.2 <span class="product-label-link" type="condition" conceptid="437541" conceptname="Glaucoma">Glaucoma</span></h2>
<p class="First"><span class="Bold">ILUVIEN</span> is contraindicated in patients with <span class="product-label-link" type="condition" conceptid="437541" conceptname="Glaucoma">glaucoma</span>, who have cup to disc ratios of greater than 0.8.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="LH0434400e47a-7402-11df-93f2-0800200c9a66"></a><a name="section-4.3"></a><p></p>
<h2>4.3 <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">Hypersensitivity</span></h2>
<p class="First"><span class="Bold">ILUVIEN</span> is contraindicated in patients with a known <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">hypersensitivity</span> to any components of this product.</p>
</div>
</div>
<div class="Section" data-sectionCode="43685-7">
<a name="LH054400e47b-7402-11df-93f2-0800200c9a66"></a><a name="section-5"></a><p></p>
<h1>5  WARNINGS AND PRECAUTIONS</h1>
<div class="Section" data-sectionCode="42229-5">
<a name="LH0514400e47c-7402-11df-93f2-0800200c9a66"></a><a name="section-5.1"></a><p></p>
<h2>5.1  Intravitreal Injection-related Effects</h2>
<p class="First">Intravitreal injections, including those with <span class="Bold">ILUVIEN</span>, have been associated with <span class="product-label-link" type="condition" conceptid="438411" conceptname="Endophthalmitis">endophthalmitis</span>, <span class="product-label-link" type="condition" conceptid="376709" conceptname="Discharge of eye">eye inflammation</span>, <span class="product-label-link" type="condition" conceptid="4011560" conceptname="Raised intraocular pressure">increased intraocular pressure</span>, and <span class="product-label-link" type="condition" conceptid="378414" conceptname="Retinal detachment">retinal detachments</span>.  Patients should be monitored following the intravitreal injection <span class="Italics">[see <a href="#LH1744010b80-7402-11df-93f2-0800200c9a66"> Patient Counseling Information (17)</a>]</span>.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="LH0524400e47d-7402-11df-93f2-0800200c9a66"></a><a name="section-5.2"></a><p></p>
<h2>5.2  Steroid-related Effects</h2>
<p class="First">Use of corticosteroids including <span class="Bold">ILUVIEN</span> may produce <span class="product-label-link" type="condition" conceptid="375256" conceptname="Anterior subcapsular polar senile cataract">posterior subcapsular cataracts</span>, <span class="product-label-link" type="condition" conceptid="4011560" conceptname="Raised intraocular pressure">increased intraocular pressure</span> and <span class="product-label-link" type="condition" conceptid="437541" conceptname="Glaucoma">glaucoma</span>. <br>Use of corticosteroids may enhance the establishment of secondary ocular <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infections</span> due to bacteria, fungi, or viruses. </p>
<p>Corticosteroids are not recommended to be used in patients with a history of ocular herpes simplex because of the potential for reactivation of the <span class="product-label-link" type="condition" conceptid="440029" conceptname="Viral disease">viral infection</span>.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="LH0534400f50a9566-2c43-11e4-8c21-0800200c9a66"></a><a name="section-5.3"></a><p></p>
<h2>5.3   Risk of Implant Migration</h2>
<p class="First">Patients in whom the posterior capsule of the lens is absent or has a tear are at risk of implant migration into the anterior chamber.</p>
</div>
</div>
<div class="Section" data-sectionCode="34084-4">
<a name="LH064400e47e-7402-11df-93f2-0800200c9a66"></a><a name="section-6"></a><p></p>
<h1>6  ADVERSE REACTIONS</h1>
<div class="Section" data-sectionCode="42229-5">
<a name="LH0614400e47f-7402-11df-93f2-0800200c9a66"></a><a name="section-6.1"></a><p></p>
<h2>6.1 Clinical Studies Experience</h2>
<p class="First">Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in practice.</p>
<p>Adverse reactions associated with ophthalmic steroids including <span class="Bold">ILUVIEN</span> include <span class="product-label-link" type="condition" conceptid="375545" conceptname="Cataract">cataract</span> formation and subsequent <span class="product-label-link" type="condition" conceptid="375545" conceptname="Cataract">cataract</span> surgery, elevated intraocular pressure, which may be associated with optic <span class="product-label-link" type="condition" conceptid="381732" conceptname="Nerve injury">nerve damage</span>, visual acuity and field defects, secondary ocular <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infection</span> from pathogens including herpes simplex, and perforation of the globe where there is thinning of the cornea or sclera.</p>
<p><span class="Bold">ILUVIEN</span> was studied in two multicenter, randomized, sham-controlled, masked trials in which patients with <span class="product-label-link" type="condition" conceptid="380097" conceptname="Diabetic macular edema">diabetic macular edema</span> were treated with either ILUVIEN (n=375) or sham (n=185). </p>
<p><a href="#table1">Table 1</a> summarizes safety data available when the last subject completed the last 36 month follow up visit for the two primary <span class="Bold">ILUVIEN</span> trials. In these trials, subjects were eligible for retreatment no earlier than 12 months after study entry.  Over the three year follow up period, approximately 75% of the <span class="Bold">ILUVIEN</span> treated subjects received only one <span class="Bold">ILUVIEN</span> implant.</p>
<p>The most common ocular (study eye) and non-ocular adverse reactions are shown in <a href="#table1">Tables 1</a> and <a href="#table2">2</a>:</p>
<a name="table1"></a><table class="Noautorules" width="650">
<caption><span>Table 1: Ocular Adverse Reactions Reported by ≥1% of Patients and
										Non-ocular Adverse Reactions Reported by ≥5% of Patients</span></caption>
<tfoot>
<tr><td colspan="5">
<span class="Sup">1</span> Includes <span class="product-label-link" type="condition" conceptid="375545" conceptname="Cataract">cataract</span>, <span class="product-label-link" type="condition" conceptid="373769" conceptname="Nuclear cataract">cataract nuclear</span>, <span class="product-label-link" type="condition" conceptid="375256" conceptname="Anterior subcapsular polar senile cataract">cataract subcapsular</span>, <span class="product-label-link" type="condition" conceptid="432895" conceptname="Cortical senile cataract">cataract cortical</span> and <span class="product-label-link" type="condition" conceptid="375545" conceptname="Cataract">cataract</span> diabetic in patients who were phakic at baseline. Among these patients, 80% of <span class="Bold">ILUVIEN</span> subjects vs. 27% of sham-controlled subjects underwent <span class="product-label-link" type="condition" conceptid="375545" conceptname="Cataract">cataract</span> surgery.</td></tr>
<tr><td colspan="5">
<span class="Sup">2</span> 235 of the 375 <span class="Bold">ILUVIEN</span> subjects were phakic at baseline; 121 of 185 sham-controlled subjects were phakic at baseline. </td></tr>
</tfoot>
<tbody class="Headless">
<tr>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top"><span class="Bold">Adverse Reactions</span></td>
<td class="Botrule Lrule Rrule Toprule" align="center"><span class="Bold">ILUVIEN <br>(N=375) <br>n  (%)</span></td>
<td class="Botrule Lrule Rrule Toprule" align="center"><span class="Bold">Sham <br>(N=185) <br>n (%)</span></td>
</tr>
<tr><td class="Bold Botrule Lrule Rrule" align="center" colspan="3">Ocular</td></tr>
<tr>
<td class="Botrule Lrule Rrule" align="center"><span class="product-label-link" type="condition" conceptid="375545" conceptname="Cataract">Cataract</span><span class="Sup">1</span>
</td>
<td class="Botrule Lrule Rrule" align="center">192/235<span class="Sup">2</span> (82%)</td>
<td class="Botrule Lrule Rrule" align="center">61/121<span class="Sup">2</span> (50%)</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="center"><span class="product-label-link" type="condition" conceptid="4034681" conceptname="Vitreous floaters">Myodesopsia</span></td>
<td class="Botrule Lrule Rrule" align="center">80 (21%)</td>
<td class="Botrule Lrule Rrule" align="center">17 (9%)</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="center"><span class="product-label-link" type="condition" conceptid="379031" conceptname="Pain in eye">Eye pain</span></td>
<td class="Botrule Lrule Rrule" align="center">57 (15%)</td>
<td class="Botrule Lrule Rrule" align="center">25 (14%)</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="center"><span class="product-label-link" type="condition" conceptid="378756" conceptname="Conjunctival hemorrhage">Conjunctival hemorrhage</span></td>
<td class="Botrule Lrule Rrule" align="center">50 (13%)</td>
<td class="Botrule Lrule Rrule" align="center">21 (11%)</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="center"><span class="product-label-link" type="condition" conceptid="4132632" conceptname="Posterior capsule opacification">Posterior capsule opacification</span></td>
<td class="Botrule Lrule Rrule" align="center">35 (9%)</td>
<td class="Botrule Lrule Rrule" align="center">6 (3%)</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="center"><span class="product-label-link" type="condition" conceptid="4049206" conceptname="Burning sensation in eye">Eye irritation</span></td>
<td class="Botrule Lrule Rrule" align="center">30 (8%)</td>
<td class="Botrule Lrule Rrule" align="center">11 (6%)</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="center"><span class="product-label-link" type="condition" conceptid="4202518" conceptname="Vitreous detachment">Vitreous detachment</span></td>
<td class="Botrule Lrule Rrule" align="center">26 (7%)</td>
<td class="Botrule Lrule Rrule" align="center">12 (7%)</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="center"><span class="product-label-link" type="condition" conceptid="379019" conceptname="Conjunctivitis">Conjunctivitis</span></td>
<td class="Botrule Lrule Rrule" align="center">14 (4%)</td>
<td class="Botrule Lrule Rrule" align="center">5 (3%)</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="center"><span class="product-label-link" type="condition" conceptid="377875" conceptname="Idiopathic corneal edema">Corneal oedema</span></td>
<td class="Botrule Lrule Rrule" align="center">13 (4%)</td>
<td class="Botrule Lrule Rrule" align="center">3 (2%)</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="center">Foreign body sensation in eyes</td>
<td class="Botrule Lrule Rrule" align="center">12 (3%)</td>
<td class="Botrule Lrule Rrule" align="center">4 (2%)</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="center"><span class="product-label-link" type="condition" conceptid="4254270" conceptname="Itching of eye">Eye pruritus</span></td>
<td class="Botrule Lrule Rrule" align="center">10 (3%)</td>
<td class="Botrule Lrule Rrule" align="center">3 (2%)</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="center"><span class="product-label-link" type="condition" conceptid="442546" conceptname="Red eye">Ocular hyperaemia</span></td>
<td class="Botrule Lrule Rrule" align="center">10 (3%)</td>
<td class="Botrule Lrule Rrule" align="center">3 (2%)</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="center"><span class="product-label-link" type="condition" conceptid="372914" conceptname="Optic atrophy">Optic atrophy</span></td>
<td class="Botrule Lrule Rrule" align="center">9 (2%)</td>
<td class="Botrule Lrule Rrule" align="center">2 (1%)</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="center"><span class="product-label-link" type="condition" conceptid="372912" conceptname="Visual discomfort">Ocular discomfort</span></td>
<td class="Botrule Lrule Rrule" align="center">8 (2%)</td>
<td class="Botrule Lrule Rrule" align="center">1 (1%)</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="center"><span class="product-label-link" type="condition" conceptid="4260194" conceptname="Photophobia">Photophobia</span></td>
<td class="Botrule Lrule Rrule" align="center">7 (2%)</td>
<td class="Botrule Lrule Rrule" align="center">2 (1%)</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="center"><span class="product-label-link" type="condition" conceptid="4220027" conceptname="Cotton wool spots">Retinal exudates</span></td>
<td class="Botrule Lrule Rrule" align="center">7 (2%)</td>
<td class="Botrule Lrule Rrule" align="center">0 (0%)</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="center"><span class="product-label-link" type="condition" conceptid="4081011" conceptname="Anterior chamber cells">Anterior chamber cell</span></td>
<td class="Botrule Lrule Rrule" align="center">6 (2%)</td>
<td class="Botrule Lrule Rrule" align="center">1 (1%)</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="center"><span class="product-label-link" type="condition" conceptid="4080696" conceptname="Discharge from eye">Eye discharge</span></td>
<td class="Botrule Lrule Rrule" align="center">6 (2%)</td>
<td class="Botrule Lrule Rrule" align="center">1 (1%)</td>
</tr>
<tr><td class="Bold Botrule Lrule Rrule" align="center" colspan="3">Non-ocular</td></tr>
<tr>
<td class="Botrule Lrule Rrule" align="center"><span class="product-label-link" type="condition" conceptid="439777" conceptname="Anemia">Anemia</span></td>
<td class="Botrule Lrule Rrule" align="center">40 (11%)</td>
<td class="Botrule Lrule Rrule" align="center">10 (5%)</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="center"><span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">Headache</span></td>
<td class="Botrule Lrule Rrule" align="center">33 (9%)</td>
<td class="Botrule Lrule Rrule" align="center">11 (6%)</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="center"><span class="product-label-link" type="condition" conceptid="192359" conceptname="Renal failure syndrome">Renal Failure</span></td>
<td class="Botrule Lrule Rrule" align="center">32 (9%)</td>
<td class="Botrule Lrule Rrule" align="center">10 (5%)</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="center"><span class="product-label-link" type="condition" conceptid="255848" conceptname="Pneumonia">Pneumonia</span></td>
<td class="Botrule Lrule Rrule" align="center">28 (7%)</td>
<td class="Botrule Lrule Rrule" align="center">8 (4%)</td>
</tr>
</tbody>
</table>
<p class="Italics Underline"><span class="product-label-link" type="condition" conceptid="4011560" conceptname="Raised intraocular pressure">Increased intraocular Pressure</span></p>
<a name="table2"></a><table class="Noautorules" width="700">
<caption><span>Table 2: Summary of Elevated IOP Related Adverse Reactions</span></caption>
<col width="10%">
<col width="5%">
<col width="5%">
<tbody class="Headless">
<tr>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top"><span class="Bold">Event</span></td>
<td class="Botrule Lrule Rrule Toprule" align="center"><span class="Bold">ILUVIEN <br>(N=375) <br>n  (%)</span></td>
<td class="Botrule Lrule Rrule Toprule" align="center"><span class="Bold">Sham <br>(N=185) <br>n (%)</span></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="center">IOP elevation ≥ 10 mmHg from Baseline</td>
<td class="Botrule Lrule Rrule" align="center">127 (34%)</td>
<td class="Botrule Lrule Rrule" align="center">18 (10%)</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="center">IOP elevation ≥ 30 mmHg</td>
<td class="Botrule Lrule Rrule" align="center">75 (20%)</td>
<td class="Botrule Lrule Rrule" align="center">8 (4%)</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="center">Any IOP-lowering medication</td>
<td class="Botrule Lrule Rrule" align="center">144 (38%)</td>
<td class="Botrule Lrule Rrule" align="center">26 (14%)</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="center">Any <span class="product-label-link" type="condition" conceptid="4121697" conceptname="Surgery">surgical intervention</span> for elevated intraocular pressure</td>
<td class="Botrule Lrule Rrule" align="center">18 (5%)</td>
<td class="Botrule Lrule Rrule" align="center">1 (1%)</td>
</tr>
</tbody>
</table>
<p><span class="ParagraphCaption">Figure 1: Mean IOP during the study</span></p>
<p><img alt="iluvien-figure-1" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=4400e471-7402-11df-93f2-0800200c9a66&amp;name=iluvien-figure-1.jpg"></p>
<p><span class="Italics Underline"><span class="product-label-link" type="condition" conceptid="375545" conceptname="Cataract">Cataracts</span> and <span class="product-label-link" type="condition" conceptid="375545" conceptname="Cataract">Cataract</span> Surgery</span><br>At baseline, 235 of the 375 <span class="Bold">ILUVIEN</span> subjects were phakic; 121 of 185 sham-controlled subjects were phakic. The incidence of <span class="product-label-link" type="condition" conceptid="375545" conceptname="Cataract">cataract</span> development in patients who had a phakic study eye was higher in the <span class="Bold">ILUVIEN</span> group (82%) compared with Sham (50%). The median time of <span class="product-label-link" type="condition" conceptid="375545" conceptname="Cataract">cataract</span> being reported as an adverse event was approximately 12 months in the <span class="Bold">ILUVIEN</span> group and 19 months in the Sham group. Among these patients, 80% of <span class="Bold">ILUVIEN</span> subjects vs. 27% of sham-controlled subjects underwent <span class="product-label-link" type="condition" conceptid="375545" conceptname="Cataract">cataract</span> surgery, generally within the first 18 months (Median Month 15 for both <span class="Bold">ILUVIEN</span> group and for Sham) of the studies.
								</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="LH0624400e47f-7402-11df-93f2-0800200c9a66"></a><a name="section-6.2"></a><p></p>
<h2>6.2 Postmarketing Experience</h2>
<p class="First">The following reactions have been identified during post-marketing use of <span class="Bold">ILUVIEN</span> in clinical practice. Because they are reported voluntarily estimates of frequency cannot be made. The reactions, which have been chosen for inclusion due to either their seriousness, frequency of reporting, possible causal connection to <span class="Bold">ILUVIEN</span>, or a combination of these factors, include reports of <span class="product-label-link" type="condition" conceptid="4168611" conceptname="Effect of drug maladministration">drug administration error</span> and reports of the drug being ineffective.</p>
</div>
</div>
<div class="Section" data-sectionCode="43684-0">
<a name="LH084400e480-7402-11df-93f2-0800200c9a66"></a><a name="section-7"></a><p></p>
<h1>8  USE IN SPECIFIC POPULATIONS</h1>
<div class="Section" data-sectionCode="42228-7">
<a name="LH0814400e481-7402-11df-93f2-0800200c9a66"></a><a name="section-7.1"></a><p></p>
<h2>8.1  Pregnancy</h2>
<p class="First">Pregnancy Category C</p>
<p>There are no adequate and well-controlled studies of <span class="Bold">ILUVIEN</span> in pregnant women. Animal reproduction studies have not been conducted with fluocinolone acetonide. Corticosteroids have been shown to be teratogenic in laboratory animals when administered systemically at relatively low dosage levels. <span class="Bold">ILUVIEN</span> should be used during pregnancy only if the potential benefit justifies the potential risk to the fetus.
								</p>
</div>
<div class="Section" data-sectionCode="34080-2">
<a name="LH0834400e482-7402-11df-93f2-0800200c9a66"></a><a name="section-7.2"></a><p></p>
<h2>8.3 Nursing Mothers</h2>
<p class="First">Systemically administered corticosteroids are present in human milk and could suppress growth and interfere with endogenous corticosteroid production. The systemic concentration of fluocinolone acetonide following intravitreal treatment with <span class="Bold">ILUVIEN</span> is low [see Clinical Pharmacology <a href="#LH1234400e488-7402-11df-93f2-0800200c9a66"> (12.3)</a>].  It is not known whether intravitreal treatment with <span class="Bold">ILUVIEN</span> could result in sufficient systemic absorption to produce detectable quantities in human milk. Exercise caution when <span class="Bold">ILUVIEN</span> is administered to a nursing woman.</p>
</div>
<div class="Section" data-sectionCode="34081-0">
<a name="LH0844400e483-7402-11df-93f2-0800200c9a66"></a><a name="section-7.3"></a><p></p>
<h2>8.4  Pediatric Use</h2>
<p class="First">Safety and effectiveness of <span class="Bold">ILUVIEN</span> in pediatric patients have not been established.</p>
</div>
<div class="Section" data-sectionCode="34082-8">
<a name="LH0854400e484-7402-11df-93f2-0800200c9a66"></a><a name="section-7.4"></a><p></p>
<h2>8.5  Geriatric Use</h2>
<p class="First">No overall differences in safety or effectiveness have been observed between elderly and younger patients.</p>
</div>
</div>
<div class="Section" data-sectionCode="34089-3">
<a name="LH114400e485-7402-11df-93f2-0800200c9a66"></a><a name="section-8"></a><p></p>
<h1>11  DESCRIPTION</h1>
<p class="First"><span class="Bold">ILUVIEN</span> is a sterile non-bioerodable intravitreal implant containing 0.19 mg (190 mcg) fluocinolone acetonide in a 36-month sustained-release drug delivery system.  <span class="Bold">ILUVIEN</span> is designed to release fluocinolone acetonide at an initial rate of 0.25 µg/day. <span class="Bold">ILUVIEN</span> is preloaded into a single-use applicator to facilitate injection of the implant directly into the vitreous. The drug substance is a synthetic corticosteroid, fluocinolone acetonide.</p>
<p>The chemical name for fluocinolone acetonide is (6α,11β, 16α)-6,9-difluoro-11,21-dihydroxy-16,17-[(1-methylethylidene)bis-(oxy)]-pregna-1,4-diene-3,20-dione. Its chemical structure is:</p>
<p><img alt="iluvien-figure-2" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=4400e471-7402-11df-93f2-0800200c9a66&amp;name=iluvien-figure-2.jpg"></p>
<p>MW 452.50; molecular formula C<span class="Sub">24</span>H<span class="Sub">30</span>F<span class="Sub">2</span>0<span class="Sub">6</span></p>
<p>Fluocinolone acetonide is a white or almost white, microcrystalline powder, practically insoluble in water, soluble in methanol, ethanol, chloroform and acetone, and sparingly soluble in ether.</p>
<p>Each <span class="Bold">ILUVIEN</span> consists of a light brown 3.5mm x 0.37mm implant containing 0.19 mg of the active ingredient fluocinolone acetonide and the following inactive ingredients:  polyimide tube, polyvinyl alcohol, silicone adhesive and water for injection.</p>
</div>
<div class="Section" data-sectionCode="34090-1">
<a name="LH124400e486-7402-11df-93f2-0800200c9a66"></a><a name="section-9"></a><p></p>
<h1>12  CLINICAL PHARMACOLOGY</h1>
<div class="Section" data-sectionCode="43679-0">
<a name="LH1214400e487-7402-11df-93f2-0800200c9a66"></a><a name="section-9.1"></a><p></p>
<h2>12.1  Mechanism of Action</h2>
<p class="First">Corticosteroids inhibit inflammatory responses to a variety of inciting agents. They inhibit <span class="product-label-link" type="condition" conceptid="433595" conceptname="Edema">edema</span>, fibrin deposition, capillary dilation, leukocyte migration, capillary proliferation, fibroblast proliferation, deposition of collagen, and <span class="product-label-link" type="condition" conceptid="4050007" conceptname="Scar">scar</span> formation associated with <span class="product-label-link" type="condition" conceptid="4053015" conceptname="Inflammation">inflammation</span>.</p>
<p>Corticosteroids are thought to act by inhibition of phospholipase A<span class="Sub">2</span> via induction of inhibitory proteins collectively called lipocortins. It is postulated that these proteins control biosynthesis of potent mediators of <span class="product-label-link" type="condition" conceptid="4053015" conceptname="Inflammation">inflammation</span> such as prostaglandins and leukotrienes by inhibiting release of the common precursor, arachidonic acid. Arachidonic acid is released from membrane phospholipids by phospholipase A<span class="Sub">2</span>.</p>
</div>
<div class="Section" data-sectionCode="43682-4">
<a name="LH1234400e488-7402-11df-93f2-0800200c9a66"></a><a name="section-9.2"></a><p></p>
<h2>12.3  Pharmacokinetics</h2>
<p class="First">In a human pharmacokinetic study of <span class="Bold">ILUVIEN</span>, fluocinolone acetonide concentrations in plasma were below the lower limit of quantitation of the assay (100 pg/mL) at all post-administration time points from Day 7 through Month 36 following intravitreal administration of a 0.2 mcg/day or 0.5 mcg/day fluocinolone acetonide insert.</p>
</div>
</div>
<div class="Section" data-sectionCode="43680-8">
<a name="LH134400e489-7402-11df-93f2-0800200c9a66"></a><a name="section-10"></a><p></p>
<h1>13  NONCLINICAL TOXICOLOGY</h1>
<div class="Section" data-sectionCode="34083-6">
<a name="LH1314400e48a-7402-11df-93f2-0800200c9a66"></a><a name="section-10.1"></a><p></p>
<h2>13.1  Carcinogenesis, Mutagenesis, Impairment of Fertility</h2>
<p class="First">Long-term animal studies have not been conducted to determine the carcinogenic potential or the effect on fertility of <span class="Bold">ILUVIEN</span>.</p>
<p>Fluocinolone acetonide was not genotoxic <span class="Italics">in vitro</span> in the Ames test (S. typhimurium and E. coli) and the mouse <span class="product-label-link" type="condition" conceptid="432571" conceptname="Malignant lymphoma">lymphoma</span> TK assay, or <span class="Italics">in vivo</span> in the mouse bone marrow micronucleus assay.</p>
</div>
</div>
<div class="Section" data-sectionCode="34092-7">
<a name="LH144400e48b-7402-11df-93f2-0800200c9a66"></a><a name="section-11"></a><p></p>
<h1>14  CLINICAL STUDIES</h1>
<p class="First">The efficacy of <span class="Bold">ILUVIEN</span> was assessed in two three year, randomized (2:1, active: sham), multicenter, double-masked, parallel-groups studies that enrolled patients with <span class="product-label-link" type="condition" conceptid="380097" conceptname="Diabetic macular edema">diabetic macular edema</span> that had previously been treated with laser photocoagulation.</p>
<p>The primary efficacy endpoint in both trials was the proportion of subjects in whom vision had improved by 15 letters or more from baseline after 24 months of follow-up.
						</p>
<a name="table3"></a><table cellpadding="2" class="Noautorules" width="800">
<caption><span>Table 3: Baseline BCVA (Letters)</span></caption>
<col width="20%">
<tbody class="Headless">
<tr>
<td class="Lrule Rrule Toprule" align="center" colspan="1"></td>
<td class="Botrule Lrule Rrule Toprule" align="center" colspan="2"><span class="Bold">Study 1</span></td>
<td class="Botrule Lrule Rrule Toprule" align="center" colspan="2"><span class="Bold">Study 2</span></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule Toprule" align="center"></td>
<td class="Botrule Lrule Rrule Toprule" align="center"><span class="Bold">ILUVIEN<br>(N=190)</span></td>
<td class="Botrule Lrule Rrule Toprule" align="center"><span class="Bold">Sham<br>(N=95)</span></td>
<td class="Botrule Lrule Rrule Toprule" align="center"><span class="Bold">ILUVIEN<br>(N=186)</span></td>
<td class="Botrule Lrule Rrule Toprule" align="center"><span class="Bold">Sham<br>(N=90)</span></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule Toprule"><span class="Bold">Mean (SD)<br>Median (Range)</span></td>
<td class="Botrule Lrule Rrule Toprule" align="center">53 (13)<br>57 (19-75)</td>
<td class="Botrule Lrule Rrule Toprule" align="center">55 (11)<br>58 (25-69)</td>
<td class="Botrule Lrule Rrule Toprule" align="center">53 (12)<br>56 (20-70)</td>
<td class="Botrule Lrule Rrule Toprule" align="center">55 (11)<br>58 (21-68)</td>
</tr>
</tbody>
</table>
<a name="table4"></a><table cellpadding="5" class="Noautorules" width="800">
<caption><span>Table 4: Visual Acuity outcomes at Month 24 (All randomized subjects with LOCF)</span></caption>
<col width="4%">
<col width="36%">
<col width="15%">
<col width="15%">
<col width="30%">
<tfoot><tr><td colspan="5">    <span class="Sup">a</span>Study 1: <span class="Bold">ILUVIEN</span>, N=190; Sham, N=95
										<br>    <span class="Sup">b</span>Study 2: <span class="Bold">ILUVIEN</span>, N=186; Sham, N=90</td></tr></tfoot>
<tbody class="Headless">
<tr>
<td class="Botrule Lrule Rrule Toprule" valign="top"><span class="Bold">  Study  <br>  </span></td>
<td class="Botrule Lrule Rrule Toprule" valign="top"><span class="Bold">  Outcomes</span></td>
<td class="Botrule Lrule Rrule Toprule" valign="top"><span class="Bold">  ILUVIEN</span></td>
<td class="Botrule Lrule Rrule Toprule" valign="top"><span class="Bold">  Sham</span></td>
<td class="Botrule Lrule Rrule Toprule" valign="top"><span class="Bold">  Estimated Difference (95% CI)</span></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule Toprule" rowspan="3" valign="top">  <br>  1<span class="Sup">a</span>
</td>
<td class="Botrule Lrule Rrule Toprule" valign="top">  Gain of ≥15 letters in BCVA (n (%))</td>
<td class="Botrule Lrule Rrule Toprule" valign="top">  51 (27%)</td>
<td class="Botrule Lrule Rrule Toprule" valign="top">  14 (15%)</td>
<td class="Botrule Lrule Rrule Toprule" valign="top">  12.1% (2.6%, 21.6%)</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule Toprule" valign="top">  Loss of ≥15 letters in BCVA (n (%))</td>
<td class="Botrule Lrule Rrule Toprule" valign="top">  26 (14%)</td>
<td class="Botrule Lrule Rrule Toprule" valign="top">  5 (5%)</td>
<td class="Botrule Lrule Rrule Toprule" valign="top">  8.4% (1.8%, 15.1%)</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule Toprule" valign="top">  Mean change from baseline  in BCVA (SD)</td>
<td class="Botrule Lrule Rrule Toprule" valign="top">  3.7 (18.7)</td>
<td class="Botrule Lrule Rrule Toprule" valign="top">  3.2 (13.1)</td>
<td class="Botrule Lrule Rrule Toprule" valign="top">  1.8 (-2.8, 6.3)</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule Toprule" rowspan="3" valign="top">  <br>  2<span class="Sup">b</span>
</td>
<td class="Botrule Lrule Rrule Toprule" valign="top">  Gain of ≥15 letters in BCVA (n (%))</td>
<td class="Botrule Lrule Rrule Toprule" valign="top">  57 (31%)</td>
<td class="Botrule Lrule Rrule Toprule" valign="top">  16 (18%)</td>
<td class="Botrule Lrule Rrule Toprule" valign="top">  13.0% (2.7%, 23.4%)</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule Toprule" valign="top">  Loss of ≥15 letters in BCVA (n (%))</td>
<td class="Botrule Lrule Rrule Toprule" valign="top">  22 (12%)</td>
<td class="Botrule Lrule Rrule Toprule" valign="top">  9 (10%)</td>
<td class="Botrule Lrule Rrule Toprule" valign="top">  1.8% (-5.9%, 9.6%)</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule Toprule" valign="top">  Mean change from baseline  in BCVA (SD)</td>
<td class="Botrule Lrule Rrule Toprule" valign="top">  5.2 (18.0)</td>
<td class="Botrule Lrule Rrule Toprule" valign="top">  0.0 (15.6)</td>
<td class="Botrule Lrule Rrule Toprule" valign="top">  6.1 (1.4, 10.8)</td>
</tr>
</tbody>
</table>
<p>Visual acuity outcomes by lens status (Phakic or Pseudophakic) at different visits are presented in <a href="#fig03">Figure 2</a> and <a href="#fig04">Figure 3</a>. The occurrence of <span class="product-label-link" type="condition" conceptid="375545" conceptname="Cataract">cataracts</span> impacted visual acuity during the study. Patients who were pseudophakic at baseline achieved greater mean BCVA change from baseline at the Month 24 study visit.</p>
<p><a name="fig03"></a><span class="ParagraphCaption">Figure 2: Proportion of subjects with &gt;=15 Letters Improvement from Baseline BCVA in the Study Eye</span></p>
<p><a name="fig3"></a><img alt="iluvien-figure-3" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=4400e471-7402-11df-93f2-0800200c9a66&amp;name=iluvien-figure-3.jpg"></p>
<p><a name="fig04"></a><span class="ParagraphCaption">Figure 3: Mean BCVA Change from Baseline</span></p>
<p><a name="fig4"></a><img alt="iluvien-figure-4" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=4400e471-7402-11df-93f2-0800200c9a66&amp;name=iluvien-figure-4.jpg"></p>
<p>The BCVA outcomes for the Pseudophakic and Phakic subgroups from Studies 1 and 2 at Month 24 are presented in <a href="#table5">Table 5</a>.</p>
<a name="table5"></a><table cellpadding="5" class="Noautorules" width="800">
<caption><span>Table 5: Visual Acuity outcomes at Month 24 (Subgroup for pooled data with LOCF)</span></caption>
<col width="12%">
<col width="35%">
<col width="15%">
<col width="15%">
<col width="23%">
<tfoot><tr><td colspan="5">    <span class="Sup">a</span>Pseudophakic : <span class="Bold">ILUVIEN</span>, N=140; Sham, N=64
										<br>    <span class="Sup">b</span>Phakic: <span class="Bold">ILUVIEN</span>, N=236; Sham, N=121</td></tr></tfoot>
<tbody class="Headless">
<tr>
<td class="Botrule Lrule Rrule Toprule" valign="top"><span class="Bold">  Lens Status</span></td>
<td class="Botrule Lrule Rrule Toprule" valign="top"><span class="Bold">  Outcomes</span></td>
<td class="Botrule Lrule Rrule Toprule" valign="top"><span class="Bold">  ILUVIEN</span></td>
<td class="Botrule Lrule Rrule Toprule" valign="top"><span class="Bold">  Sham</span></td>
<td class="Botrule Lrule Rrule Toprule" valign="top"><span class="Bold">  Estimated Difference   (95% CI)</span></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule Toprule" rowspan="3" valign="top">  <br>  <span class="Sup">a</span>Pseudophakic</td>
<td class="Botrule Lrule Rrule Toprule" valign="top">  Gain of ≥15 letters in BCVA (n (%))</td>
<td class="Botrule Lrule Rrule Toprule" valign="top">  39 (28%)</td>
<td class="Botrule Lrule Rrule Toprule" valign="top">  8 (13%)</td>
<td class="Botrule Lrule Rrule Toprule" valign="top">  15.4% (4.4%, 26.3%)</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule Toprule" valign="top">  Loss of ≥15 letters in BCVA (n (%))</td>
<td class="Botrule Lrule Rrule Toprule" valign="top">  7 (5%)</td>
<td class="Botrule Lrule Rrule Toprule" valign="top">  7 (11%)</td>
<td class="Botrule Lrule Rrule Toprule" valign="top">  -5.9% (-14.4%, 2.5%)</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule Toprule" valign="top">  Mean change from baseline  in BCVA <br>  (SD)</td>
<td class="Botrule Lrule Rrule Toprule" valign="top">  7.1 (14.5)</td>
<td class="Botrule Lrule Rrule Toprule" valign="top">  1.5 (17.4)</td>
<td class="Botrule Lrule Rrule Toprule" valign="top">  5.6 (0.7, 10.6)</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule Toprule" rowspan="3" valign="top">  <br>  <span class="Sup">b</span>Phakic</td>
<td class="Botrule Lrule Rrule Toprule" valign="top">  Gain of ≥15 letters in BCVA (n (%))</td>
<td class="Botrule Lrule Rrule Toprule" valign="top">  69 (29%)</td>
<td class="Botrule Lrule Rrule Toprule" valign="top">  22 (18%)</td>
<td class="Botrule Lrule Rrule Toprule" valign="top">  11.1% (2.1%, 20.1%)</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule Toprule" valign="top">  Loss of ≥15 letters in BCVA (n (%))</td>
<td class="Botrule Lrule Rrule Toprule" valign="top">  41 (17%)</td>
<td class="Botrule Lrule Rrule Toprule" valign="top">  7 (6%)</td>
<td class="Botrule Lrule Rrule Toprule" valign="top">  11.6% (5.2%, 18%)</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule Toprule" valign="top">  Mean change from baseline  in BCVA <br>  (SD)</td>
<td class="Botrule Lrule Rrule Toprule" valign="top">  2.8 (20.1)</td>
<td class="Botrule Lrule Rrule Toprule" valign="top">  1.8 (12.6)</td>
<td class="Botrule Lrule Rrule Toprule" valign="top">  1 (-2.5 ,4.4)</td>
</tr>
</tbody>
</table>
</div>
<div class="Section" data-sectionCode="34069-5">
<a name="LH164400e48c-7402-11df-93f2-0800200c9a66"></a><a name="section-12"></a><p></p>
<h1>16  HOW SUPPLIED/STORAGE AND HANDLING</h1>
<p class="First"><span class="Bold">ILUVIEN®</span> (fluocinolone acetonide intravitreal implant) 0.19 mg is supplied in a sterile single use preloaded applicator with a 25-gauge needle, packaged in a tray sealed with a lid inside a carton.
						</p>
<p>NDC 68611-190-02</p>
<div class="Section" data-sectionCode="44425-7">
<a name="LHS4400e48d-7402-11df-93f2-0800200c9a66"></a><a name="section-12.1"></a><p></p>
<p class="First"><span class="Bold">Storage:</span>  Store at 15° - 30° C (59° - 86° F).</p>
</div>
</div>
<div class="Section" data-sectionCode="34076-0">
<a name="LH1744010b80-7402-11df-93f2-0800200c9a66"></a><a name="section-13"></a><p></p>
<h1>17  PATIENT COUNSELING INFORMATION</h1>
<p class="First"><span class="Bold">Steroid-related Effects</span><br>
							Advise patients that a <span class="product-label-link" type="condition" conceptid="375545" conceptname="Cataract">cataract</span> may occur after treatment with <span class="Bold">ILUVIEN</span>.  If this occurs, advise patients that their vision will decrease, and they will need an operation to remove the <span class="product-label-link" type="condition" conceptid="375545" conceptname="Cataract">cataract</span> and restore their vision.
						</p>
<p>Advise patients that they may develop <span class="product-label-link" type="condition" conceptid="4011560" conceptname="Raised intraocular pressure">increased intraocular pressure</span> with <span class="Bold">ILUVIEN</span> treatment, and the increased IOP may need to be managed with eye drops, or surgery.</p>
<p><span class="Bold">Intravitreal Injection-related Effects</span><br>
							Advise patients that in the days following intravitreal injection of <span class="Bold">ILUVIEN</span>, patients are at risk for potential complications including in particular, but not limited to, the development of <span class="product-label-link" type="condition" conceptid="438411" conceptname="Endophthalmitis">endophthalmitis</span> or elevated intraocular pressure.
						</p>
<p><span class="Bold">When to Seek Physician Advice</span><br>
							Advise patients that if the eye becomes red, sensitive to light, painful, or develops a change in vision, they should seek immediate care from an ophthalmologist.
						</p>
<p><span class="Bold">Driving and Using Machines</span><br> 
							Inform patients that they may experience temporary visual blurring after receiving an intravitreal injection. Advise patients not to drive or use machines until this has been resolved.<br><br></p>
<p>Manufactured for: <br>
							Alimera Sciences, Inc.<br>
							6120 Windward Parkway<br>
							Alpharetta, GA 30005<br><br><br></p>
<p>Patented. See: www.alimerasciences.com</p>
<p><span class="Bold Underline">ALIMERA</span><br>SCIENCES</p>
</div>
<div class="Section" data-sectionCode="51945-4">
<a name="LHC44010b83-7402-11df-93f2-0800200c9a66"></a><a name="section-14"></a><p></p>
<p class="First"><span class="Bold">Package Label - Principal Display Panel – Carton</span></p>
<p><img alt="Carton" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=4400e471-7402-11df-93f2-0800200c9a66&amp;name=iluvien-figure-5.jpg"></p>
<p>   </p>
</div>
<div class="Section" data-sectionCode="51945-4">
<a name="LHI44010b84-7402-11df-93f2-0800200c9a66"></a><a name="section-15"></a><p></p>
<p class="First"><span class="Bold">Package Label - Principal Display Panel – Lid</span></p>
<p><img alt="Lid" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=4400e471-7402-11df-93f2-0800200c9a66&amp;name=iluvien-figure-6.jpg"></p>
</div>
<div class="Section" data-sectionCode="51945-4">
<a name="SB2100"></a><a name="section-16"></a><p></p>
<p class="First"><span class="Bold">Package Label - Principal Display Panel – Inserter</span></p>
<p><img alt="Inserter" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=4400e471-7402-11df-93f2-0800200c9a66&amp;name=iluvien-figure-7.jpg"></p>
</div>
</div>
<div class="DataElementsTables">
<table class="contentTablePetite" cellSpacing="0" cellPadding="3" width="100%"><tbody>
<tr><td class="contentTableTitle">
<strong>ILUVIEN 		
					</strong><br><span class="contentTableReg">fluocinolone acetonide implant</span>
</td></tr>
<tr><td><table width="100%" cellpadding="5" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Information</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Product Type</td>
<td class="formItem">HUMAN PRESCRIPTION DRUG LABEL</td>
<td class="formLabel">Item Code (Source)</td>
<td class="formItem">NDC:68611-190</td>
</tr>
<tr class="formTableRow">
<td width="30%" class="formLabel">Route of Administration</td>
<td class="formItem">INTRAVITREAL</td>
<td width="30%" class="formLabel">DEA Schedule</td>
<td class="formItem">    
							</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="3" class="formHeadingTitle">Active Ingredient/Active Moiety</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Basis of Strength</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">
<strong>FLUOCINOLONE ACETONIDE</strong> (FLUOCINOLONE ACETONIDE) </td>
<td class="formItem">FLUOCINOLONE ACETONIDE</td>
<td class="formItem">0.19 mg</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="2" class="formHeadingTitle">Inactive Ingredients</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>POLYVINYL ALCOHOL</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>WATER</strong></td>
<td class="formItem"> </td>
</tr>
</table></td></tr>
<tr><td></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="5" class="formHeadingTitle">Packaging</td></tr>
<tr>
<th scope="col" width="1" class="formTitle">#</th>
<th scope="col" class="formTitle">Item Code</th>
<th scope="col" class="formTitle">Package Description</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">1</th>
<td class="formItem">NDC:68611-190-02</td>
<td class="formItem">1  in 1 CARTON</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">1</th>
<td class="formItem"></td>
<td class="formItem">1  in 1 TRAY</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">1</th>
<td class="formItem"></td>
<td class="formItem">1  in 1 APPLICATOR</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
</table></td></tr>
<tr><td></td></tr>
<tr><td class="normalizer"><table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Marketing Information</span></td></tr>
<tr>
<th scope="col" class="formTitle">Marketing Category</th>
<th scope="col" class="formTitle">Application Number or Monograph Citation</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">NDA</td>
<td class="formItem">NDA201923</td>
<td class="formItem">10/15/2014</td>
<td class="formItem"></td>
</tr>
</table></td></tr>
</tbody></table>
<table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite"><tr><td colspan="4" class="formHeadingReg">
<span class="formHeadingTitle">Labeler - </span>Alimera Sciences, Inc.
							(135745292)
						</td></tr></table>
<table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Establishment</span></td></tr>
<tr>
<th scope="col" class="formTitle">Name</th>
<th scope="col" class="formTitle">Address</th>
<th scope="col" class="formTitle">ID/FEI</th>
<th scope="col" class="formTitle">Business Operations</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">Alimera Sciences, Inc.</td>
<td class="formItem"></td>
<td class="formItem">135745292</td>
<td class="formItem">LABEL(68611-190)</td>
</tr>
</table>
</div>
<p><div class="EffectiveDate">Revised: 12/2014<div class="DocumentMetadata">
<div>
<a href="javascript:toggleMixin();">Document Id: </a>7e9f69be-77a9-4b2d-843f-9e094ac3f9f6</div>
<div>Set id: 4400e471-7402-11df-93f2-0800200c9a66</div>
<div>Version: 8</div>
<div>Effective Time: 20141204</div>
</div>
</div> <div class="DistributorName">Alimera Sciences, Inc.</div></p>
</body></html>
